title: Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis.
abstract: Therapeutic plasma exchange (TPE), is a procedure, changing pathologic substances in the plasma of patients with replacement fluid. TPE has an increasing list of indications in recent years such as neurological, connective tissue, hematological, nephrological, endocrinological and metabolic disorders. We report our multicenter data about therapeutic plasma exchange in patients with neurological diseases. Six University Hospitals' aphaeresis units medical records about neurologic diseases were reviewed retrospectively. Hundred and fifteen patients and 771 TPE sessions from six aphaeresis units' were included to this study. Of the 115 patients, 53 (46%) were men and 62 (54%) were women. The median age was 50 (range: 5-85) years. Of these patients 58.3% were Guillain-Barre syndrome (GBS), 17.4% were acute disseminated encephalomyelitis (ADEM), 10.4% were chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 7% were multiple sclerosis, 6.1% were myasthenia gravis (MG) and 0.9% were Wilson disease (WD). The median number of TPE sessions per patient was 5 (range 1-72). Human albumin was used as a replacement fluid in 66% and fresh frozen plasma was used in 34% of cases. TPE was done through central venous catheters in 66%, and peripheral venous access in 34% of patients. Some complications were seen in patients (18.3%) during TPE sessions. These complications were, complications related to catheter placement procedure (8.7%), hypotension (3.5%), hypocalcaemia (3.5%) and allergic reactions (1.7%). The complication ratios were 2.7% in total 771 TPE procedures. TPE procedure was terminated in 6% of sessions depending on these complications. Overall responses to TPE were noted in 89.5% of patients. In conclusion; Therapeutic plasma exchange is an effective treatment option in several neurologic diseases.
authors.affiliation: Inonu University Medical School, Department of Hematology and Aphaeresis Unit, Malatya, Turkey. emin.kaya@inonu.edu.tr
authors.forename: Emin
authors.initials: E
authors.lastname: Kaya
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Keklik
authors.forename: Mehmet
authors.initials: M
authors.lastname: Sencan
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yilmaz
authors.forename: Ali
authors.initials: A
authors.lastname: Keskin
authors.forename: Ilhami
authors.initials: I
authors.lastname: Kiki
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Erkurt
authors.forename: Serdar
authors.initials: S
authors.lastname: Sivgin
authors.forename: Serdal
authors.initials: S
authors.lastname: Korkmaz
authors.forename: Vahap
authors.initials: V
authors.lastname: Okan
authors.forename: Mehmet Hilmi
authors.initials: MH
authors.lastname: Doğu
authors.forename: Ali
authors.initials: A
authors.lastname: Unal
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cetin
authors.forename: Fevzi
authors.initials: F
authors.lastname: Altuntaş
authors.forename: Osman
authors.initials: O
authors.lastname: Ilhan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000627:therapeutic use; D001781:Blood Component Removal / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D004673:Encephalomyelitis, Acute Disseminated / Q000628:therapy*; D005260:Female; D020275:Guillain-Barre Syndrome / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000628:therapy*; D009157:Myasthenia Gravis / Q000628:therapy*; D010951:Plasma Exchange / Q000379:methods*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000418:Albumins